Biotech Values

[jmkobers]

<<Bottom line: As a MNTA shareholder, I now feel slightly more confident that MNTA will get Copaxone approval before MYL.>>

That's it? Slightly more confident??

What happened to the bravado? I.e, Teva has no chance of approval (merely a knockoff) and Amphastar has even LESS of a shot (their submission is a total joke and in tatters)??

This brush with reality could actually wind up being the most bullish signal MNTA has gotten in years, if ever